Glioma

P=N/A, N=2000, Recruiting, Nanfang Hospital, Southern Medical University

P1, N=30, Recruiting, Children's Hospital of Philadelphia | Trial completion date: Dec 2026 --> Dec 2027 | Trial primary completion date: Dec 2025 --> Dec 2026

To enhance staging performance, a logistic regression-based machine learning algorithm was utilized, showing 100% accuracy in classifying healthy controls and low- and high-grade cases. This work provides instructive insights into development of next-generation renewable ECL biosensors and data algorithm models, paving the way for early glioma diagnostics, tumor staging, and pathogenesis research.

MCA is a valuable tool for understanding the complex interdependence of prognostic markers in gliomas. MCA facilitates the exploration of large-scale datasets and enhances the identification of significant associations.

Genetic analysis identified a rare nonsense NF1 variant (p.Gln83Ter), also found in other affected family members, providing valuable insight into genotype-phenotype correlation. This case highlights several important points such as the need for a high index of suspicion in young children presenting with unusual or coexisting ocular manifestations, the utility of early genetic confirmation for diagnosis and family counseling, and the importance of coordinated, multidisciplinary care to address the diverse and progressive complications of NF1.

This case expands the known clinical and radiological spectrum of PXA, highlighting that it can occur in older patients, in uncommon locations, and with atypical imaging features. It underscores the importance of histopathological and molecular analysis for definitive diagnosis and supports gross total resection as the mainstay of treatment.

While not significantly associated with tumor grade or patient demographics, MMRD may have clinical relevance in specific subgroups. NGS findings highlight the potential utility of integrating molecular diagnostics for identifying MSI and guiding immunotherapy decisions.

FACS analysis showed loss of co-stimulatory CD80, an immune synapse component, following B3gat1 knockdown. These results suggest that loss of HNK-1 expression contributes to tumor immune escape through loss of immune recognition and attack via downregulation of tumor cell surface co-stimulatory molecules, leading to reduced CD8+ T-cell activation and immune synapse formation, and increased T-cell apoptosis.

P=N/A, N=228, Not yet recruiting, Institut du Cancer de Montpellier - Val d'Aurelle | Trial completion date: Apr 2028 --> Oct 2028 | Trial primary completion date: Oct 2026 --> Apr 2027

P1, N=12, Not yet recruiting, Neonc Technologies, Inc. | Trial completion date: Oct 2025 --> Oct 2026 | Trial primary completion date: Oct 2025 --> Oct 2026

P1, N=11, Active, not recruiting, Memorial Sloan Kettering Cancer Center | Recruiting --> Active, not recruiting | N=30 --> 11

Sirtinol was detected in the brains of sirtinol-treated mice, suggesting blood brain barrier penetrance. Conclusions : Based on our results, sirtinol shows promise as a selective, redox-modulating therapeutic for DIPG that enhances oxidative stress and interferes with DNA repair.